We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oridis Licenses NIH's Proprietary Tissue Microarray Technology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oridis Licenses NIH's Proprietary Tissue Microarray Technology "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Oridis Biomed has announced that it has entered into a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH's proprietary Tissue microarray (TMA) technology.

"We are pleased to have been granted by the NIH a license for this TMA technology," said Georg Casari, PhD, Head of ORIDIS Biomed's TISSOMICS™ business.

"This license agreement further strengthens our TISSOMICS™ business for the life-science industry worldwide, where we offer our clients the ability to validate their research, such as biomarker and target verification programs."

Tissue microarrays are a research tool, within Oridis Biomed's TISSOMICS™ platform, that is designed to permit the study of several hundred tissue samples, using standardized high-throughput analysis by in-house pathologists.